Key Highlights

  • GSK has completed its $10.6 billion acquisition of Nuvalent, paying $124 per share in cash.
  • 91.3% of Nuvalent’s outstanding shares were tendered, satisfying the deal’s minimum condition.
  • Nuvalent’s stock has been delisted from NASDAQ following the merger’s completion on July 15, 2026.
  • The transaction was funded through GSK’s credit facilities, with no shareholder vote required.

Deal Finalized at $124 Per Share

Nuvalent has been acquired by GlaxoSmithKline in an all-cash transaction valued at $10.6 billion. The deal, which closed on July 15, 2026, priced each share at $124, marking a definitive end to the company’s public trading status. The acquisition was structured as a tender offer, with GSK’s subsidiary, Harmony Row Acquisition Co. leading the process.

The $124 per-share price reflects a premium to Nuvalent’s recent trading levels, though shares had already climbed 22.9% year-to-date before the deal’s announcement. The transaction’s equity value aligns with the company’s $9.8 billion market capitalization just prior to the merger’s completion. For investors, the deal removes any further upside from Nuvalent’s pipeline but delivers immediate liquidity at a fixed price.

Mechanics of the Tender and Merger

The tender offer launched on June 24, 2026, and expired at 11:59 p.m. Eastern Time on July 14. By the deadline, 72,518,967 shares, representing 91.3% of Nuvalent’s outstanding stock, had been validly tendered.

This included 67,083,713 Class A shares (90.7% of the total) and all 5,435,254 Class B shares, satisfying the minimum condition set in the merger agreement. Following the tender’s success, GSK’s subsidiary merged with Nuvalent on July 15, with the company continuing as a wholly owned subsidiary under the same name. The merger was executed under Delaware law without requiring a shareholder vote.

As part of the process, all outstanding stock options and restricted stock units were canceled and converted into cash payments based on the $124 offer price. The deal’s structure ensured that dissenting shareholders received the same per-share consideration as those who tendered.

Why the Move Matters Now

Nuvalent’s shares, up 22.9% year-to-date and trading near their 52-week high of $123.99, had already reflected much of the deal’s premium before the merger’s completion. The stock’s 0.4% gain over the past month suggests investors were pricing in a high probability of the transaction closing without complications. With a market capitalization of $9.8 billion, the company had become a significant player in oncology, making it an attractive target for GSK’s expansion in precision medicine.

The all-cash structure removes any lingering uncertainty for shareholders, while GSK gains full control of Nuvalent’s pipeline without the need for further integration risks. The deal also signals GSK’s confidence in Nuvalent’s clinical assets, particularly its targeted therapies for genetically defined cancers. For the broader biotech sector, the acquisition underscores the value of late-stage oncology programs in a competitive M&A environment.

What Investors Should Watch Next

Nuvalent’s delisting from NASDAQ took effect on July 15, 2026, following the company’s formal request to halt trading. The next administrative step will be the filing of a Form 15 with the SEC to suspend its reporting obligations under the Exchange Act. While no further public disclosures are expected, GSK may provide updates on Nuvalent’s pipeline integration during its quarterly earnings calls.

Investors holding shares through the tender will receive their $124 per-share payment promptly, with funds sourced from GSK’s credit facilities.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.